Loading...

PLX PROTALIX BIOTHERAPEUTICS INC Product Launches 8-K Filing

PRTL

PLX

PROTALIX BIOTHERAPEUTICS INC

(PLX)

2023 8-K

Show Summary

Summary

Financial Statements

Financial Results

Bylaw Amendments

Stockholder Update

Financial Results

Clinical Trial Update

Financial Results

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Condition and Oth...

Financial Results Announcement

Agreement for Stock Sale

Financial Results Announcement

Regulation FD Disclosure

External Links:

Protalix BioTherapeutics and Chiesi Global Rare Diseases announced that the European Medicines Agency recommended marketing authorization for PRX-102 for the treatment of Fabry disease.

AI Assistant

PROTALIX BIOTHERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.